Childhood vaccinations falling due to vaccine complacency, says WHO
Immunisations against measles, whooping cough, polio, and hepatitis B remained below pre-pandemic levels in Europe and Central Asia in 2024, due largely to a sense of 'vaccine complacency' that is already causing a resurgence of preventable diseases, the agency said.
Last year, nearly 300,000 people in the region got whooping cough, more than three times as many as in 2023, the report found. More than 125,000 people got measles, the region's highest case count in more than 25 years.
'These are not just numbers – it's hundreds of thousands of families in anguish because their children are sick, and it could have been prevented,' Dr Hans Kluge, the WHO's Europe director, said in a statement.
More than half of the region's 53 countries had vaccination rates that were below the level needed to prevent outbreaks of measles, mumps, rubella, diphtheria, whooping cough, and tetanus.
Health experts often point to vaccine hesitancy to explain why more parents are opting not to immunise their children.
But Regina De Dominicis, who leads UNICEF's work in Europe and Central Asia, instead cited vaccine complacency, which is when parents believe the risks from preventable diseases are low and therefore do not see a reason to vaccinate their children.
'Today's generation has not witnessed the devastating impact of vaccine-preventable diseases – leading to complacency and making it easier for misinformation to take hold,' De Dominics said.
Improvement on some newer vaccines
Notably, Europeans are not turning away from all vaccines equally. Over the past five years, children and young people have become more likely to get vaccines that protect against human papillomavirus (HPV), rotavirus, pneumonia, and meningitis.
Several countries have introduced these jabs in recent years, which is expected to help reduce rates of HPV infections and related cervical cancer, as well as child hospitalisations from bacterial diseases, pneumonia, and rotavirus-induced diarrhoea, the WHO said.
To boost routine immunisation rates, health officials called on countries to shore up their health systems, ensure vaccines are widely available, and fight misinformation about the jabs.
'Communities must be empowered with trusted information, so parents can confidently vaccinate their children,' Kluge said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
11 hours ago
- Euronews
An average of 28 kids die daily in Gaza, UNICEF tells Security Council
An average of 28 children are killed daily in Gaza, and more than 17,000 kids have reportedly been killed in the ongoing war in the besieged Palestinian enclave, UNICEF said Wednesday. Speaking before the UN Security Council, UNICEF Executive Director Catherine Russell said each of Gaza's one million children has faced immense suffering. According to Russell, these children will face lifelong impacts. 'Over the past 21 months of war, more than 17,000 children have reportedly been killed and 33,000 injured in Gaza. An average of 28 children have been killed each day, the equivalent of an entire classroom," she said. "Consider that for a moment: a whole classroom of children killed every day for nearly two years. These children are not combatants – they are being killed and maimed as they line up for lifesaving food and medicine.' In Israel's response to recent reports of its strikes in Gaza killing dozens of children, the Israeli military maintained it remained 'committed to the rule of law.' According to the Israel Defence Force, a 10 July attack that killed at least 10 children waiting to receive nutritional supplements at a Project Hope-run medical clinic in Deir al-Balah, Gaza Strip, was caused by a "technical error." The strike targeting an Islamic Jihad "terrorist" caused the munition to fall dozens of metres from the target, it said. The incident is under review, the military added. Increasing deaths come amid food shortages The growing number of deaths of children, women, and civilians in strikes on Gaza. The number comes amid food supplies running out. UN humanitarian chief Tom Fletcher told the Security Council on Wednesday that civilians are being shot while seeking something to eat. "Civilians are exposed to death and injury, forcible displacement, and stripped of dignity,' Fletcher told the U.N. Security Council, emphasising Israel's obligation under the Geneva Conventions to provide food and medical aid as the occupying power in Gaza. He also challenged the council to consider whether Israel's rules of engagement incorporate all the precautions to avoid and minimise civilian casualties. Meanwhile, at least twenty Palestinians were killed at a food distribution in the Gaza Strip on Wednesday, mostly from a stampede. The Gaza Humanitarian Foundation accused the Hamas militant group of fomenting unrest at the food distribution centre, causing the stampede. They were the first deaths reported at one of the food distribution centres run by an Israeli-backed American organisation, though hundreds have been killed by Israeli forces on the roads leading to them, according to witnesses and health officials.
Euronews
11 hours ago
- Euronews
Why some countries' healthcare spending is more wasteful than others
Wealthy countries spend trillions of euros on health care every year, but not all of them are getting their money's worth, a new analysis has found. Higher levels of health spending are linked to better outcomes, but after a certain point, more money may not be efficient or practical. The more a country spends on medical care, the more it must pay to continue boosting citizens' health, according to the study published in The Lancet Global Health journal. In countries that spend $100 (€85) per capita on health care, for example, spending another $92 (€79) per person earns them an additional year of healthy life. But in countries that spend $5,000 (€4,272) per capita, another healthy year would cost $11,213 (€9,580). 'Countries around the world have made significant progress in converting dollars into health,' wrote the researchers from the US-based Institute for Health Metrics and Evaluation (IHME). 'However, more reductions in inefficiency need to be made in an era of tightening health-care budgets [and] to maximise the returns on their health care spending'. The researchers determined health spending inefficiency by comparing a country's total health spending – including the amount they spend and how they spend it – to the number of years people there can expect to live in good health. The study included 201 countries and territories, and covered a 28-year period from 1995 to 2022. Drivers of efficient and wasteful spending Globally, health spending became more efficient between 1995 and 2019, but this progress was disrupted during the COVID-19 pandemic. While it began to recover in 2022, there are still major 'inefficiency gaps' between countries, the analysis found. The United States spends more per capita on healthcare than any other wealthy country. But its system is not particularly efficient, which costs Americans 6.2 years of healthy life. China was the most efficient country with zero waste, meaning it optimised its spending to deliver the best possible health outcomes for its citizens, according to the analysis. Most European countries were considered fairly efficient. Exceptions included Ukraine, Lithuania, Latvia, and to a lesser extent, the Netherlands, Belgium, Belarus, Finland, Norway, and the United Kingdom. Beyond their actual budgets, the most efficient countries tended to have better governance, greater uptake of primary care, infrastructure that makes it possible for people to access medical services, and more public spending on health care compared with the private sector. Notably, the study does not take into account health care quality, but rather tracks how well a country scores among those with similar levels of spending. The study authors said policymakers could use the findings to maximise their investments in health, which could be particularly important given many countries are facing pressure on their budgets. 'Expanding government-provided health-care coverage would decrease the inefficiency of the health care system,' the researchers argued. 'Countries should also focus on strengthening democracy, building infrastructure, and increasing the use of, and access to, preventive care,' they added.
Euronews
a day ago
- Euronews
Trump officials are pushing psychedelic therapy. Will it help or hurt?
For decades, proponents of psychedelic drugs have pushed a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for patients grappling with depression, trauma and other hard-to-treat conditions. In the United States, a presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' US health secretary Robert F Kennedy Jr recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. The Trump administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants, and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organisation has pursed the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved'". US regulators may reconsider MDMA Under former US President Joe Biden, the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD), citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first US approval of a psychedelic for medical use, and European researchers said it likely set the field back there as well. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new programme promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. Links to psychedelic advocates US health agencies also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardise patients. "If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.' Nora Volkow, the longtime director of the US National Institute on Drug Abuse, said her agency remains interested in psychedelics. It is funding a US drugmaker that's working to develop a safer, synthetic version of ibogaine, which is a potent psychedelic made from a shrub that's native to West Africa. Texas recently launched a $50 million (€42.7 million) trial to test ibogaine as a treatment for opioid addiction, PTSD, and other conditions. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them".
